Neuro biomarker platform Cognision offers an FDA-cleared, cloud-powered EEG/ERP system and an integrated Cognision360 platform that consolidates EEG, ERP, PSG, eye tracking, wearables, and digital assessments for CNS trials, presenting a comprehensive data ecosystem for neuroscience-focused clinical customers.

Clinical trial momentum System has been implemented in multiple CNS clinical trials and is positioned as a precision biomarker solution, indicating ongoing adoption potential among biotech and pharma sponsors seeking objective neurocognitive endpoints.

Early stage scale With 11-50 employees and revenue in the low-to-mid single digits, Cognision is likely receptive to scalable partnerships, channel programs, and pilot collaborations to expand reach without long sales cycles.

Strategic alliances Founding member of the EEG/ERP Biomarker Qualification Consortium signals credibility and potential access to alliance-driven opportunities, co-development, and joint engagement with larger CNS programs.

Expansion opportunities Recent press indicates a unified platform launch for neurobiomarker data, suggesting cross-sell potential to existing trial customers and opportunities to upsell additional data streams, analytics, and eCOA/ePRO integrations.